Beam Therapeutics
Price & Volume
Stats
See moreOpen | $30.36 |
Previous Close | $30.48 |
Day Range | $29.11-$30.36 |
52W Range | $16.02-$38.26 |
Market Cap | $3.1B |
Shares Short | 24M |
Financials
See moreRevenue (12 Mos) | $156M |
Revenue Growth (YoY) | -94.2% |
Gross Profit (12 Mos) | -$252.6M |
Diluted EPS | -$0.69 |
News
See moreYahoo Finance • 4 days ago
Biotech Breakout: What's in focus after Moderna's cancer win?
Yahoo Finance • 5 days ago
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Yahoo Finance • 25 days ago
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Yahoo Finance • 26 days ago
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
About
CEO | Mr. John M. Evans M.B.A. |
Address | 238 Main Street, Cambridge, MA, United States, 02142 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 540 |